Fibrocell Science (FCSC.OB) Meets All FDA Requirements for Skin Treatment Product

QualityStocks would like to highlight Fibrocell Science (OTCBB: FCSC). The company’s lead therapy, azficel-T, is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient's own natural fibroblasts are extracted, multiplied, and re-injected as personalized therapy to regenerate skin. Fibroblasts are cells that contribute to the formation of connective tissue fibers, and regenerative fibroblast cells may have potential in use for broad aesthetic, medical, and scientific applications.

In the company’s news yesterday,

Fibrocell Science announced it has submitted its complete response to the U.S. Food and Drug Administration (FDA) concerning the company’s Biologics License Application for azficel-T.

Submitting the response brings the company into full compliance with the FDA in regards to azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and winkles.

“The submission of our response to the FDA is a significant milestone for our lead cell therapy, azficel-T,” David Pernock, Fibrocell Science chairman and CEO stated in the press release. “We believe that we have now satisfied all of the FDA requirements.”

One of the FDA requirements was to conduct a histopathological study to examine the skin after the administration of injections of azficel-T. In the clinical study, azficel-T was compared to a placebo and untreated skin in each of the 29 patients. The company said the results were consistent with previous clinical studies, and that at three months the study provided sufficient data to support the profile seen in the clinic.

“Azficel-T was directly compared to a placebo injection as well as untreated skin in each subject. The study results were consistent with previous clinical studies, while providing a detailed examination of azficel-T activity at the microscopic level after repeated injections,” said James Merritt, M.D., Clinical Advisor to the study and chief medical officer of CBR International Corp., a Colorado based research firm who provided medical advice to Fibrocell during the study. “The study met all expectations, and importantly raised no safety concerns.”

According to the Prescription Drug User Fee Act (PDUFA), the FDA will have six months to review the data submission once they deem that the response from Fibrocell Science is complete.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.